Breaking News, Financial News

Financial Reports: ImmunoGen

Targeted Antibody Payload technology begins to pay off

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

ImmunoGen 4Q13 4Q Revenues: $3.8 million (+30%) 4Q Loss: $21.9 million (loss of $22.4 million in 2Q12) FY Revenues: $35.5 million (+117%) FY Loss: $72.8 million (loss of $73.3 million in 2Q12) Comments: ImmunoGen advanced several pipeline antibody-drug conjugates during the quarter. Cancer treatment Kadcyla was launched by partner Genentech/Roche late in 3Q13; ImmunoGen will receive royalties one quarter after sales are reported. FY revenues were boosted by a $10.5 million milestone from Ro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters